Methamphetamine influences on brain and behavior: Unsafe at any speed?

Trends in Neurosciences

Volumn 35, Issue 9, 2012, Pages 536-545

  Marshall, John F ^a   O'Dell, Steven J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Addiction; Amphetamines; Dopamine; Recognition memory; Serotonin; Striatum

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; GLUTAMIC ACID; INDOLEAMINE; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NORADRENALIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SEROTONIN;

BEHAVIOR; BEHAVIOR CHANGE; BLOOD BRAIN BARRIER; BRAIN FUNCTION; BRAIN INJURY; CELL ACTIVITY; COGNITION; COGNITIVE DEFECT; CORPUS STRIATUM; DECISION MAKING; EXECUTIVE FUNCTION; HUMAN; MEMORY; MONOAMINERGIC SYSTEM; NERVE ENDING; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PLACE PREFERENCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TASK PERFORMANCE;

ANIMALS; BEHAVIOR; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; MENTAL DISORDERS; METHAMPHETAMINE;

EID: 84865572863     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2012.05.006     Document Type: Review

References (108)

1. Suwaki H., et al. Methamphetamine abuse in Japan: its 45 year history and the current situation. Amphetamine Misuse: International Perspectives on Current Trends 1997, 199-214. Harwood. H. Klee (Ed.).
2. Prinzmetal M., Bloomberg W. Use of benzidrine for the treatment of narcolepsy. J. Am. Med. Assoc. 1935, 105:2051-2054.
3. Penick S.B. Amphetamines on obesity. Semin. Psychiatry 1969, 1:144-162.
4. Lambert N.M., et al. Hyperactive children and the efficacy of psychoactive drugs as a treatment intervention. Am. J. Orthopsychiatry 1976, 46:335-352.
5. Feldman R.S., et al. Principles of Neuropsychopharmacology 1997, Sinauer Associates.
6. Koob G.F., Le Moal M. Neurobiology of Addiction 2006, Elsevier.
7. Cook C.E., et al. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab. Dispos. 1993, 21:717-723.
8. Sulzer D., et al. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 2005, 75:406-433.
9. Vollm B.A., et al. Methamphetamine activates reward circuitry in drug naive human subjects. Neuropsychopharmacology 2004, 29:1715-1722.
10. 11C]WIN 35,428 - positron emission tomography studies. Neurosci. Lett. 1998, 258:17-20.
11. 11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J. Neurosci. 1998, 18:419-427.
12. Yamamoto B.K., Raudensky J. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J. Neuroimmune Pharmacol. 2008, 3:203-217.
13. Cadet J.L., Krasnova I.N. Molecular bases of methamphetamine-induced neurodegeneration. Int. Rev. Neurobiol. 2009, 88:101-119.
14. Fleckenstein A.E., et al. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology 2009, 56(Suppl. 1):133-138.
15. Yamamoto B.K., et al. Amphetamine toxicities: classical and emerging mechanisms. Ann. N.Y. Acad. Sci. 2010, 1187:101-121.
16. Ricaurte G.A., et al. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 1982, 235:93-103.
17. Bowyer J.F., Schmued L.C. Fluoro-Ruby labeling prior to an amphetamine neurotoxic insult shows a definitive massive loss of dopaminergic terminals and axons in the caudate-putamen. Brain Res. 2006, 1075:236-239.
18. Pu C., Vorhees C.V. Protective effects of MK-801 on methamphetamine-induced depletion of dopaminergic and serotonergic terminals and striatal astrocytic response: an immunohistochemical study. Synapse 1995, 19:97-104.
19. Miller D.B., O'Callaghan J.P. Elevated environmental temperature and methamphetamine neurotoxicity. Environ. Res. 2003, 92:48-53.
20. LaVoie M.J., et al. Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp. Neurol. 2004, 187:47-57.
21. Thomas D.M., et al. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci. Lett. 2004, 367:349-354.
22. Segal D.S., et al. Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 2003, 28:1730-1740.
23. Belcher A.M., et al. Impaired object recognition memory following methamphetamine, but not p-chloroamphetamine- or d-amphetamine-induced neurotoxicity. Neuropsychopharmacology 2005, 30:2026-2034.
24. Schwendt M., et al. Extended methamphetamine self-administration in rats results in a selective reduction of dopamine transporter levels in the prefrontal cortex and dorsal striatum not accompanied by marked monoaminergic depletion. J. Pharmacol. Exp. Ther. 2009, 331:555-562.
25. Kuczenski R., et al. Escalating dose-multiple binge methamphetamine exposure results in degeneration of the neocortex and limbic system in the rat. Exp. Neurol. 2007, 207:42-51.
26. Krasnova I.N., et al. Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat. PLoS ONE 2010, 5:e8790.
27. O'Dell S.J., et al. Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res. 1991, 564:256-260.
28. Nash J.F., Yamamoto B.K. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res. 1992, 581:237-243.
29. Mark K.A., et al. High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J. Neurosci. 2004, 24:11449-11456.
30. Berman S.B., et al. Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J. Neurochem. 1996, 67:593-600.
31. Wrona M.Z., et al. Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration. NIDA Res. Monogr. 1997, 173:146-174.
32. Kuhn D.M., et al. Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Ann. N.Y. Acad. Sci. 2006, 1074:31-41.
33. Dykens J.A., et al. Mechanism of kainate toxicity to cerebellar neurons in vitro is analogous to reperfusion tissue injury. J. Neurochem. 1987, 49:1222-1228.
34. Dumuis A., et al. NMDA receptors activate the arachidonic acid cascade system in striatal neurons. Nature 1988, 336:68-70.
35. Radi R., et al. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem. 1991, 266:4244-4250.
36. Quinton M.S., Yamamoto B.K. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J. 2006, 8:E337-E347.
37. Berman S.B., Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 1999, 73:1127-1137.
38. Brown J.M., et al. Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite. J. Neurochem. 2005, 95:429-436.
39. Casamenti F., et al. Interleukin-1beta activates forebrain glial cells and increases nitric oxide production and cortical glutamate and GABA release in vivo: implications for Alzheimer's disease. Neuroscience 1999, 91:831-842.
40. Zou J.Y., Crews F.T. TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res. 2005, 1034:11-24.
41. Northrop N.A., Yamamoto B.K. Neuroimmune pharmacology from a neuroscience perspective. J. Neuroimmune Pharmacol. 2011, 6:10-19.
42. Staszewski R.D., Yamamoto B.K. Methamphetamine-induced spectrin proteolysis in the rat striatum. J. Neurochem. 2006, 96:1267-1276.
43. Straiko M.M., et al. The effect of amphetamine analogs on cleaved microtubule-associated protein-tau formation in the rat brain. Neuroscience 2007, 144:223-231.
44. Kiyatkin E.A., et al. Brain edema and breakdown of the blood-brain barrier during methamphetamine intoxication: critical role of brain hyperthermia. Eur. J. Neurosci. 2007, 26:1242-1253.
45. Bowyer J.F., et al. Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood-brain barrier in the caudate-putamen from acute methamphetamine exposure. Synapse 2008, 62:193-204.
46. 11C]WIN-35,428. J. Neurosci. 1998, 18:8417-8422.
47. Volkow N.D., et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry 2001, 158:377-382.
48. Wilson J.M., et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 1996, 2:699-703.
49. Moszczynska A., et al. Why is parkinsonism not a feature of human methamphetamine users?. Brain 2004, 127:363-370.
50. Sekine Y., et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch. Gen. Psychiatry 2006, 63:90-100.
51. Kish S.J., et al. Brain serotonin transporter in human methamphetamine users. Psychopharmacology (Berl.) 2009, 202:649-661.
52. Sekine Y., et al. Methamphetamine causes microglial activation in the brains of human abusers. J. Neurosci. 2008, 28:5756-5761.
53. Stoll G., Jander S. The role of microglia and macrophages in the pathophysiology of the CNS. Prog. Neurobiol. 1999, 58:233-247.
54. Loane D.J., Byrnes K.R. Role of microglia in neurotrauma. Neurotherapeutics 2010, 7:366-377.
55. Kettenmann H., et al. Physiology of microglia. Physiol. Rev. 2011, 91:461-553.
56. Simon S.L., et al. Cognitive impairment in individuals currently using methamphetamine. Am. J. Addict. 2000, 9:222-231.
57. Boileau I., et al. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker?. J. Neurosci. 2008, 28:9850-9856.
58. Ornstein T.J., et al. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology 2000, 23:113-126.
59. Kim S.J., et al. Frontal glucose hypometabolism in abstinent methamphetamine users. Neuropsychopharmacology 2005, 30:1383-1391.
60. Chung A., et al. Decreased frontal white-matter integrity in abstinent methamphetamine abusers. Int. J. Neuropsychopharmacol. 2007, 10:765-775.
61. Kim Y.T., et al. Dose-dependent frontal hypometabolism on FDG-PET in methamphetamine abusers. J. Psychiatr. Res. 2009, 43:1166-1170.
62. Salo R., et al. Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals. Psychiatry Res. 2002, 111:65-74.
63. Nordahl T.E., et al. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J. Neuropsychiatry Clin. Neurosci. 2003, 15:317-325.
64. Salo R., et al. Drug abstinence and cognitive control in methamphetamine-dependent individuals. J. Subst. Abuse Treat. 2009, 37:292-297.
65. Hoffman W.F., et al. Neuropsychological function and delay discounting in methamphetamine-dependent individuals. Psychopharmacology (Berl.) 2006, 188:162-170.
66. Hoffman W.F., et al. Cortical activation during delay discounting in abstinent methamphetamine dependent individuals. Psychopharmacology (Berl.) 2008, 201:183-193.
67. Izquierdo A., Jentsch J.D. Reversal learning as a measure of impulsive and compulsive behavior in addictions. Psychopharmacology (Berl.) 2012, 219:607-620.
68. Rendell P.G., et al. Prospective memory impairment in former users of methamphetamine. Psychopharmacology (Berl.) 2009, 203:609-616.
69. Meredith C.W., et al. Implications of chronic methamphetamine use: a literature review. Harv. Rev. Psychiatry 2005, 13:141-154.
70. Bisagno V., et al. Short toxic methamphetamine schedule impairs object recognition task in male rats. Brain Res. 2002, 940:95-101.
71. Schroder N., et al. Neurotoxic methamphetamine regimen severely impairs recognition memory in rats. Synapse 2003, 49:89-96.
72. O'Dell S.J., et al. A neurotoxic regimen of methamphetamine impairs novelty recognition as measured by a social odor-based task. Behav. Brain Res. 2011, 216:396-401.
73. Chapman D.E., et al. Long-term changes in basal ganglia function after a neurotoxic regimen of methamphetamine. J. Pharmacol. Exp. Ther. 2001, 296:520-527.
74. Herring N.R., et al. Effect of +-methamphetamine on path integration learning, novel object recognition, and neurotoxicity in rats. Psychopharmacology (Berl.) 2008, 199:637-650.
75. Herring N.R., et al. (+)-Methamphetamine-induced monoamine reductions and impaired egocentric learning in adrenalectomized rats is independent of hyperthermia. Synapse 2010, 64:773-785.
76. Kesner R.P., et al. Memory for spatial locations, motor responses, and objects: triple dissociation among the hippocampus, caudate nucleus, and extrastriate visual cortex. Exp. Brain Res. 1993, 93:462-470.
77. Schenk F., Morris R.G. Dissociation between components of spatial memory in rats after recovery from the effects of retrohippocampal lesions. Exp. Brain Res. 1985, 58:11-28.
78. Brown M.W., et al. Recognition memory: material, processes, and substrates. Hippocampus 2010, 20:1228-1244.
79. Feinberg L.M., et al. Recognition memory for social and non-social odors: differential effects of neurotoxic lesions to the hippocampus and perirhinal cortex. Neurobiol. Learn. Mem. 2012, 97:7-16.
80. Friedman S.D., et al. Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol. Biochem. Behav. 1998, 61:35-44.
81. Izquierdo A., et al. Reversal-specific learning impairments after a binge regimen of methamphetamine in rats: possible involvement of striatal dopamine. Neuropsychopharmacology 2010, 35:505-514.
82. Kosheleff A.R., et al. Work aversion and associated changes in dopamine and serotonin transporter after methamphetamine exposure in rats. Psychopharmacology (Berl.) 2012, 219:411-420.
83. Belcher A.M., et al. A sensitizing regimen of methamphetamine causes impairments in a novelty preference task of object recognition. Behav. Brain Res. 2006, 170:167-172.
84. Rogers J.L., et al. Extended methamphetamine self-administration enhances reinstatement of drug seeking and impairs novel object recognition in rats. Psychopharmacology (Berl.) 2008, 199:615-624.
85. Reichel C.M., et al. Loss of object recognition memory produced by extended access to methamphetamine self-administration is reversed by positive allosteric modulation of metabotropic glutamate receptor 5. Neuropsychopharmacology 2011, 36:782-792.
86. Reichel C.M., et al. Methamphetamine-induced changes in the object recognition memory circuit. Neuropharmacology 2012, 62:1119-1126.
87. Cass W.A., Manning M.W. Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine. J. Neurosci. 1999, 19:7653-7660.
88. Cass W.A. Attenuation and recovery of evoked overflow of striatal serotonin in rats treated with neurotoxic doses of methamphetamine. J. Neurochem. 2000, 74:1079-1085.
89. Melega W.P., et al. Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res. 1997, 766:113-120.
90. Harvey D.C., et al. Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res. 2000, 871:259-270.
91. Volkow N.D., et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J. Neurosci. 2001, 21:9414-9418.
92. Wang G.J., et al. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am. J. Psychiatry 2004, 161:242-248.
93. Berman S.M., et al. Changes in cerebral glucose metabolism during early abstinence from chronic methamphetamine abuse. Mol. Psychiatry 2008, 13:897-908.
94. McCann U.D., et al. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 2008, 62:91-100.
95. Cass W.A., et al. Restorative effects of GDNF on striatal dopamine release in rats treated with neurotoxic doses of methamphetamine. Ann. N.Y. Acad. Sci. 2000, 914:127-136.
96. O'Dell S.J., et al. Running wheel exercise ameliorates methamphetamine-induced damage to dopamine and serotonin terminals. Synapse 2012, 66:71-80.
97. Cotman C.W., Berchtold N.C. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 2002, 25:295-301.
98. Smith A.D., Zigmond M.J. Can the brain be protected through exercise? Lessons from an animal model of parkinsonism. Exp. Neurol. 2003, 184:31-39.
99. Navaratna D., et al. Mechanisms and targets for angiogenic therapy after stroke. Cell Adhes. Migr. 2009, 3:216-223.
100. Ma Y., et al. Vascular endothelial growth factor in cerebral ischemia. J. Neurosci. Res. 2011, 89:969-978.
101. Warburton E.C., Brown M.W. Findings from animals concerning when interactions between perirhinal cortex, hippocampus and medial prefrontal cortex are necessary for recognition memory. Neuropsychologia 2010, 48:2262-2272.
102. Barker G.R., Warburton E.C. When is the hippocampus involved in recognition memory?. J. Neurosci. 2011, 31:10721-10731.
103. McFadden L.M., et al. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. J. Pharmacol. Exp. Ther. 2012, 340:295-303.
104. Lominac K.D., et al. Distinct neurochemical adaptations within the nucleus accumbens produced by a history of self-administered vs non-contingently administered intravenous methamphetamine. Neuropsychopharmacology 2012, 37:707-722.
105. Belcher A.M., et al. Methamphetamine influences on recognition memory: comparison of escalating and single-day dosing regimens. Neuropsychopharmacology 2008, 33:1453-1463.
106. Walsh S.L., Wagner G.C. Motor impairments after methamphetamine-induced neurotoxicity in the rat. J. Pharmacol. Exp. Ther. 1992, 263:617-626.
107. Callaghan R.C., et al. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend. 2012, 120:35-40.
108. Volkow N.D., et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am. J. Psychiatry 2001, 158:2015-2021.